

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5037]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | | |
|--------------------------------------|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No issues identified during scoping. | |

- | | |
|--|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No issues raised in submissions, expert statements or academic report. | |

- | | |
|------------------------------------|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No issues identified by committee. | |

- | | |
|----|---|
| 4. | Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|----|---|

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
--

N/A

Approved by Associate Director (name): Ross Dent

Date: 13/08/2025